Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2024-08-18 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于使用部分超募资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 圣湘生物科技股份有限公司 regarding the use of part of the over-raised funds to permanently supplement working capital. It details the background of the fundraising, the amount of over-raised funds, the intended use of these funds, and includes opinions from the supervisory board and the sponsor. The document is relatively short (2652 characters) and focuses on a specific capital use decision rather than presenting comprehensive financial data or a full report. It is not an annual or interim report, nor an earnings release or management discussion. It is a formal announcement related to capital use and financing activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2024-08-18 Chinese
圣湘生物科技股份有限公司关于2024年半年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from 圣湘生物科技股份有限公司 regarding the 2024 half-year profit distribution plan. It details the dividend per share, the basis for calculation, the approval process by the board and supervisory committee, and the need for shareholder meeting approval. The document does not contain full financial statements or comprehensive financial analysis but focuses on the dividend distribution plan and related corporate governance steps. It is not a full interim or annual report, nor is it a simple notification of report publication. The content fits the category of Notice of Dividend Amount (DIV), as it announces dividend amounts, payment details, and related shareholder information.
2024-08-18 Chinese
圣湘生物科技股份有限公司2024年半年度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report". It covers the period from January 1, 2024 to June 30, 2024, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, earnings per share, and management discussion and analysis. It also contains sections on company overview, financial indicators, management discussion, and analysis, which are typical components of an interim or quarterly report. The document length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-18 Chinese
圣湘生物科技股份有限公司2024年度“提质增效重回报”行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2024年度‘提质增效重回报’行动方案的半年度评估报告" which translates to a "2024 Annual 'Quality Improvement, Efficiency Enhancement, and Return to Shareholders' Action Plan Half-Year Assessment Report." It contains detailed operational and financial performance data for the first half of 2024, including revenue, net profit, product development, international expansion, investor returns, internal controls, and management incentives. The document includes actual financial figures and substantive analysis of business trends and outlook. It is a comprehensive mid-year performance report rather than a brief announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length (5123 characters) supports it being a full report rather than a short announcement. Hence, the classification is IR with high confidence. H1 2024
2024-08-18 Chinese
圣湘生物科技股份有限公司第二届监事会2024年第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 2024 fourth meeting of the second Supervisory Board of 圣湘生物科技股份有限公司. It includes details of the meeting, voting results, and references to other documents such as the 2024 half-year report, profit distribution plan, share repurchase and capital reduction, and use of raised funds. However, the document itself does not contain the full half-year report or detailed financial statements but rather confirms the approval of these reports and plans by the Supervisory Board and refers readers to the full reports published on the Shanghai Stock Exchange website. The document length is only 2650 characters, which is relatively short and mainly serves as an announcement of meeting resolutions and approvals. According to the MENU VS MEAL RULE, this is an announcement of approvals and references to reports rather than the reports themselves. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement of meeting resolutions and approvals without substantive financial data or full report content.
2024-08-18 Chinese
圣湘生物科技股份有限公司关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 圣湘生物科技股份有限公司 regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory committee approvals, investment scope, risk control measures, and compliance with regulatory requirements. The document does not contain financial statements or detailed financial results but rather informs about the company's decision and plan to use idle raised funds for safe, liquid investment products. It is a regulatory announcement about capital management activities related to fundraising proceeds, not a full financial report or earnings release. The document length is under 5,000 characters and is an announcement of a financing-related activity. Therefore, it fits best under Capital/Financing Update (CAP).
2024-08-18 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.